Oncolytics Biotech Inc. Announces Issuance of 33rd U.S. Patent

29-Oct-2009 - Canada

Oncolytics Biotech Inc. announced that it has been granted its 33rd U.S. Patent, No. 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus." The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

"This patent supports our expanding clinical program, including our first Phase III study, looking at REOLYSIN(R) in combination with a range of chemotherapeutic agents," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "Many of our studies enroll patients that did not previously respond to chemotherapy, including our Phase III study in patients with platinum refractory head and neck cancers."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances